GlassScriptPhysician profile
Jeffrey Marlow
NPI 1679621239
$2,040.12
in general payments reported to CMS, 2019-2025
33 companies · $56.29 in 2025
The $56.29 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,029 · 2020: $125 · 2021: $178 · 2022: $501 · 2023: $104 · 2024: $46.34 · 2025: $56.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $206.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $206.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $325.74 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $247.27 | 2019-2022 | |
| Lilly USA, LLC | $238.42 | 2019-2023 | Mounjaro |
| Novo Nordisk INC | $216.54 | 2019-2022 | |
| Janssen Biotech, INC. | $108.28 | 2019-2022 | |
| Pfizer INC. | $105.55 | 2019-2020 | |
| Ucb, INC. | $86.11 | 2019-2022 | |
| Abbvie INC. | $78.89 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.76 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $62.03 | 2019-2023 | Gardasil 9 |
| Vivus LLC | $45.86 | 2019 | |
| Exact Sciences Corporation | $36.01 | 2025 | Cologuard Collection Kit |
| Teva Pharmaceuticals USA, INC. | $35.41 | 2019-2022 | |
| Corcept Therapeutics | $27.45 | 2024 | Korlym |
| Csl Behring | $25.27 | 2019 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurelis, INC. | $24.71 | 2021 | |
| Amneal Pharmaceuticals LLC | $21.59 | 2023 | Unithroid |
| Genzyme Corporation | $20.62 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.28 | 2025 | Gvoke Hypopen |
| Abbott Laboratories | $20.00 | 2023 | Freestyle Libre 3 |
| Biohaven Pharmaceuticals, INC. | $19.82 | 2021 | |
| Impel Pharmaceuticals INC. | $19.46 | 2023 | Trudhesa |
| Bayer Healthcare Pharmaceuticals INC. | $18.89 | 2024 | |
| Celgene Corporation | $18.78 | 2019 | |
| Medtronic Minimed, INC. | $17.94 | 2019 | |
| Upsher-Smith Laboratories LLC | $16.76 | 2021 | |
| Novartis Pharmaceuticals Corporation | $16.39 | 2019 | |
| Grifols USA, LLC | $16.29 | 2022 | |
| Avion Pharmaceuticals | $15.28 | 2022 | |
| Idorsia Pharmaceuticals US INC | $15.09 | 2023 | Quviviq |
| Eisai INC. | $14.93 | 2021 | |
| Insulet Corporation | $14.52 | 2019 | |
| Dexcom, INC. | $12.18 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Marlow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.